全文获取类型
收费全文 | 30915篇 |
免费 | 1907篇 |
国内免费 | 459篇 |
专业分类
耳鼻咽喉 | 139篇 |
儿科学 | 375篇 |
妇产科学 | 387篇 |
基础医学 | 1576篇 |
口腔科学 | 148篇 |
临床医学 | 2536篇 |
内科学 | 3290篇 |
皮肤病学 | 467篇 |
神经病学 | 1072篇 |
特种医学 | 440篇 |
外科学 | 1432篇 |
综合类 | 3708篇 |
预防医学 | 4263篇 |
眼科学 | 181篇 |
药学 | 10462篇 |
12篇 | |
中国医学 | 623篇 |
肿瘤学 | 2170篇 |
出版年
2023年 | 347篇 |
2022年 | 805篇 |
2021年 | 997篇 |
2020年 | 874篇 |
2019年 | 822篇 |
2018年 | 830篇 |
2017年 | 814篇 |
2016年 | 867篇 |
2015年 | 1041篇 |
2014年 | 2321篇 |
2013年 | 2738篇 |
2012年 | 2247篇 |
2011年 | 2562篇 |
2010年 | 1860篇 |
2009年 | 1757篇 |
2008年 | 1735篇 |
2007年 | 1627篇 |
2006年 | 1392篇 |
2005年 | 1121篇 |
2004年 | 886篇 |
2003年 | 729篇 |
2002年 | 549篇 |
2001年 | 490篇 |
2000年 | 435篇 |
1999年 | 439篇 |
1998年 | 280篇 |
1997年 | 267篇 |
1996年 | 205篇 |
1995年 | 212篇 |
1994年 | 210篇 |
1993年 | 155篇 |
1992年 | 152篇 |
1991年 | 101篇 |
1990年 | 101篇 |
1989年 | 84篇 |
1988年 | 101篇 |
1987年 | 95篇 |
1986年 | 97篇 |
1985年 | 110篇 |
1984年 | 123篇 |
1983年 | 66篇 |
1982年 | 71篇 |
1981年 | 52篇 |
1980年 | 63篇 |
1979年 | 49篇 |
1978年 | 57篇 |
1977年 | 52篇 |
1976年 | 59篇 |
1975年 | 65篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
2.
3.
4.
5.
《Journal of vascular and interventional radiology : JVIR》2022,33(3):249-254.e1
An ovine iliac vein thrombosis model was devised to test a wall-contacting rotational thrombectomy device. Thrombosis was successfully induced in 9 sheep with an average clot length of 31 mm ± 12 and >60% vessel occlusion on angiography. The thrombus was subsequently removed, maintaining normal intraoperative pulmonary arterial pressure (5.9 mm Hg ± 3.6) and complete distal reperfusion after thrombectomy. Additionally, the sheep were without signs of vascular trauma or embolic complications on gross necropsy and histopathologic analysis. The findings from this study support the use of an ovine iliac deep vein thrombosis model for testing of a lower extremity thrombectomy device. 相似文献
6.
7.
《Vaccine》2022,40(49):7151-7157
IntroductionRespiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new and potentially longer-lasting monoclonal antibody, Nirsevimab, showed promising results in phase IIb/III trials. We evaluate the cost-effectiveness of Nirsevimab intervention programmes in England and Wales.MethodsWe used a dynamic model for RSV transmission, calibrated to data from England and Wales. We considered a suite of potential Nirsevimab programmes, including administration to all neonates (year-round); only neonates born during the RSV season (seasonal); or neonates born during the RSV season plus infants less than six months old before the start of the RSV season (seasonal + catch-up).ResultsIf administered seasonally to all infants at birth, we found that Nirsevimab would have to be priced at £63 or less per dose for at least 50% certainty that it could cost-effectively replace the current Palivizumab programme, using an ICER threshold of £20,000/QALY. An extended seasonal programme which includes a pre-season catch-up becomes the optimal strategy at a purchasing price of £32/dose or less for at least 50% certainty. At a purchasing price per dose of £5-32, the annual implementation costs of a seasonal programme could be as high as £2 million before a switch to a year-round strategy would be optimal.DiscussionNirsevimab has the potential to be cost-effective in England and Wales not only for use in high-risk infants. 相似文献
8.
宫颈癌严重威胁全球女性的生命健康,晚期宫颈癌治疗手段有限,5年生存率不到20%,是妇科肿瘤的巨大挑战。免疫治疗是晚期宫颈癌患者的重要治疗手段之一,包括免疫检查点抑制剂、治疗性疫苗和过继性T细胞免疫疗法等,但免疫治疗耐药性使部分患者无应答而效果不佳。因此,迫切需要深入研究和探讨免疫耐药的机制从而改善耐药,现归纳总结了近年有关宫颈癌中免疫耐药机制的相关研究,主要分为肿瘤内在因素和外在免疫环境改变等因素,并介绍针对免疫耐药提出的应对措施及进展。 相似文献
9.
《Drug discovery today》2022,27(9):2551-2561
B cell lymphoma 2 (BCL2) overexpression in a range of human tumors is often related to chemotherapy resistance and poor prognosis. GC-rich regions upstream of the P1 promoter in human BCL2 can form G-quadruplex (G4) structures through the stacking of four Hoogsteen-paired guanine bases. Stabilizing the G4 fold implies the inhibition of BCL2 expression and, thus, small molecules that selectively bind to the G4 are promising anticancer candidates. In this review, we discuss the structural aspects, binding affinity, selectivity, and biological activity of well-characterized BCL2 G4 binding ligands in vitro and in vivo. We also explore future directions in the research and development of G4-based anticancer therapeutics. 相似文献
10.